Fig. 2: PFSratio-based clinical trial design. | npj Precision Oncology

Fig. 2: PFSratio-based clinical trial design.

From: Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials

Fig. 2: PFSratio-based clinical trial design.

a, b Graphic representation of the impact of correlation (rho), power, HR on sample size in PFSratio-based clinical trial design. Abbreviations: GBVE Gumbel’s type B bivariate extreme-value, kappa shape of the hazard function, rho pearson correlation index between PFS1 and PFS2, R median ratio between PFS1 and 2, detailed with corresponding δ1 and δ0.

Back to article page